Bayer : Q3 the expected strong quarter
>Q3 ahead of expectations - Q3 was the expected strong quarter for Bayer with revenue of € 11.28bn, 1% ahead of our forecast and 3% ahead of the consensus (Vara). Adjusted EBITDA was even c. 9% ahead of our forecast and 6% ahead of the consensus, but c. 4 percentage points come from a better adj. EBITDA in “Others” (-€ 87m vs our forecast of -€ 200m and -€ 155m consensus). Underlying revenue growth for the group was 5.7% y-o-y vs 5% y-o-y our forecast. Hence, FX tailw...Bayer is a life sciences group based in Germany. Co.'s operations are organized along three divisions: Pharmaceuticals (engaged in prescription pharmaceuticals for cardiology and women's healthcare); Consumer Health (engaged in non-prescription products in dermatology, dietary supplement, analgesic, gastrointestinal, allergy, cold and flu, foot care, sun protection and cardiovascular risk prevention categories); and CropScience (engaged in the development of seeds and plant traits; crop protection; and for gardens, the green industry and non-agricultural pest control). Co. also maintains an Animal Health business unit engaged in the development of products for farm and companion animals.
Oddo Securities provides securities brokerage and research services. The company offers equity, economic, and derivatives research and credit analysis services. It focuses on insurance, automotive, building materials, pharmaceuticals, telecommunications, information technology, and agri-food industries.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.